Montana bill would license clinics selling Phase I drugs

Montana lawmakers have approved legislation that would set up a state licensing system for clinics offering medical treatments that do not have federal approval. The measure is now awaiting an executive signature. If enacted, it would create state rules for how certain experimental medical products could be provided within Montana.

A central feature of the bill is a threshold that would allow providers to sell drugs that have completed Phase I clinical trials. Phase I studies are designed to evaluate basic safety and dosing. They do not establish that a treatment provides therapeutic benefit, a point that remains unresolved at the stage when sales could begin under the proposed state pathway.

Montana’s proposed licensing pathway for experimental clinics

Under the legislation, the state would establish licensing requirements for clinics that want to sell products eligible under the bill. Supporters describe the proposal as an effort to move beyond limited-access approaches by creating a clearer, formal structure for providers to operate under Montana rules.

Backers frame the measure as an expansion of existing state-level “Right to Try” statutes. With a licensing system, Montana would define how providers can legally offer treatments to patients even when those products have not been approved at the federal level.

Phase I completion as the key eligibility milestone

The bill’s main policy choice is treating completion of Phase I trials as sufficient for clinics to begin selling the drugs within the state framework. Supporters argue that a defined state regulatory structure could provide a more organized route for providers, compared with narrower mechanisms that can limit access.

Supporters’ goals: longevity therapies and medical tourism Proponents have said the legislation is intended to broaden access to longevity-focused therapies. They have also argued it could help position Montana as a destination for medical tourism, with clinics operating under a state-defined licensing regime.

Supporters further contend the proposal would strengthen individual medical autonomy by allowing patients to pursue emerging interventions earlier than they could through standard federal pathways. In their view, licensing would shift availability from ad hoc routes toward a structured framework for clinics.

Concerns: patient safety and federal-state friction Legal and ethical experts have raised concerns that permitting sales after Phase I trials could increase the risk of patient harm. They note that early-stage safety evaluations do not show that a treatment works, leaving uncertainties about meaningful clinical benefit at the point of sale.

Experts have also pointed to the broader implications of moving around established federal safety and efficacy standards. The bill could create jurisdictional tension between Montana’s licensing rules and the federal oversight role of the Food and Drug Administration, reflecting a gap between state permission to sell and the federal government’s traditional role in drug approvals.

Next steps and possible precedent beyond Montana

The proposal is being watched as a potential model for similar efforts elsewhere. If enacted, supporters in other states could cite Montana’s approach as a step beyond “Right to Try” statutes toward broader state-based regulatory structures for experimental clinics.

For now, the next development is the pending executive decision. Debate continues over whether the framework balances access, personal autonomy, and patient protection when treatments lack federal approval.